Highlights

• FY26 net profit after tax more than doubled on the prior year, as post-pandemic destocking pressures continued to unwind.

• Revenue growth was supported by a recovery in both the industrial and healthcare glove and protective equipment segments.

• Gross margins improved as input costs eased and pricing discipline held.

• The board lifted the full-year Dividend in line with the improved Earnings base.

• Ansell continued to invest in higher-margin, innovation-led product categories across its safety solutions portfolio.

• The Balance Sheet remained in a healthy position, supporting continued Investment and Shareholder returns.

Ansell has spent the past few years working through one of the more dramatic Demand swings in Australian industrial history: a pandemic-era surge in glove and protective equipment orders followed by a painful period of customer destocking that crushed volumes and margins. The FY26 result marked a decisive turn, with net profit more than doubling as the destocking cycle finally worked its way through the system and demand normalised across both industrial and healthcare markets.

Latest Developments

Ansell reported its results for the year to 30 June 2026, with management attributing the sharp profit improvement to a recovery in order volumes across both its industrial safety solutions and healthcare glove businesses, as customers' excess inventory built up during and after the Pandemic was finally worked down.

The company continued to invest in higher-margin, innovation-led categories within its safety solutions portfolio, part of a strategy to reduce its reliance on commodity-style glove products and shift the earnings mix toward differentiated, higher-value offerings.

What the Numbers Show

Net profit after tax more than doubled on the prior year, with revenue growth supported by a recovery in both the industrial and healthcare segments. Gross margins improved as input costs eased and pricing discipline held through the recovery.

The board lifted the full-year dividend in line with the improved earnings base, while the balance sheet remained in a healthy position, supporting continued investment in product innovation and ongoing shareholder returns.

What Could Drive the Stock Next

Continued normalisation of order patterns, further Margin gains from the shift toward higher-value safety solutions, and any bolt-on acquisitions that add innovation-led capability would all support the recovery narrative.

Ansell's exposure to global industrial activity and healthcare procurement cycles means broader economic conditions in its key markets, including the United States and Europe, will also shape the pace of ongoing growth.

Key Risks to Watch

The scale of the profit recovery, coming off a heavily destocked base, raises the question of how much further growth is achievable from here without a genuine step-up in underlying demand. Any renewed customer destocking or inventory correction would quickly weigh on volumes again.

Input cost volatility, particularly for raw materials such as natural rubber and nitrile, along with currency movements given Ansell's global Manufacturing and sales footprint, remain ongoing risks to margins.

Investor Takeaway

Ansell's FY26 result confirms that the painful destocking cycle has largely passed, with profit more than doubling as demand and margins recovered together. The scale of the rebound was helped by an unusually weak comparative base, so the more important question for investors is how much of this growth can be sustained once the recovery fully normalises.

This article is general information only and does not constitute financial or investment advice.